Alprazolam Orally Disintegrating Tablets CIV
Generic Name and Formulations:
Alprazolam 0.25mg, 0.5mg. 1mg, 2mg; scored tabs; orange flavor.
Various generic manufacturers
Indications for Alprazolam Orally Disintegrating Tablets:
Anxiety disorder. Short-term treatment of anxiety symptoms. Panic disorder (with or without agoraphobia).
≥18yrs: Anxiety: Initially 0.25–0.5mg three times daily. May increase at 3–4 day intervals to 4mg/day in divided doses. Panic: Initially 0.5mg three times daily; may increase at intervals of 3–4 days in increments of up to 1mg/day; usual max 10mg/day. Advanced liver disease, elderly, or debilitated: initially 0.25mg 2–3 times daily. For all: individualize; reevaluate periodically; withdraw gradually.
<18yrs: not recommended.
Acute narrow-angle glaucoma. Concomitant itraconazole, ketoconazole.
Risks from concomitant use with opioids; see Interactions. Not for use in untreated open-angle glaucoma. Discard unused portions of scored tabs (drug stability not ensured). Suicidal ideation. Depression. Psychosis. Mania. Renal, cardiovascular, hepatic, or pulmonary impairment; monitor. Obesity. Reevaluate periodically. Change dose gradually. Withdrawal symptoms on abrupt cessation or dose reduction. Monitor periodic CBCs, urinalysis, blood chemistry. Drug or alcohol abuse. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.D), nursing mothers: not recommended.
See Contraindications; other azole antifungals: not recommended. Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Additive CNS depressant effects with alcohol or other CNS depressants (eg, other benzodiazepines, psychotropics, anticonvulsants, antihistamines); consider dose reductions. Potentiated by CYP3A inhibitors (eg, cimetidine, nefazodone, fluvoxamine); reduce alprazolam dose; caution with weaker CYP3A inhibitors (eg, fluoxetine, propoxyphene, oral contraceptives). Caution with diltiazem, isoniazid, erythromycin, clarithromycin, grapefruit juice, sertraline, paroxetine, ergotamine, cyclosporine, amiodarone, nicardipine, nifedipine, others metabolized by CYP3A. Antagonized by CYP3A inducers (eg, carbamazepine). May increase levels of imipramine, desipramine. Absorption may be affected by drugs or conditions that affect salivation or gastric pH.
CNS depression (eg, sedation, somnolence, memory impairment, dysarthria, coordination abnormal, ataxia), fatigue, lethargy, dyspnea, dry mouth, constipation, withdrawal seizures, tremors, decreased libido, sexual dysfunction, paradoxical excitement.
Clinical Pain Advisor Articles
- Brain Plasticity in Patients With Complex Regional Pain Syndrome
- Perturbation-Based Rehabilitation Effective for Chronic Low Back Pain
- Cannabis Use Associated With Relationship Between Pain and Negative Affect
- FDA Expresses Safety Concern Over Kratom
- Cannabidiol Concentrations Widely Vary in Products Sold Online
- Cannabis Use Associated With Aberrant Drug Behaviors
- Walgreens to Carry Naloxone in All Pharmacies to Combat Drug Abuse
- Independent Pharmacies Expanding Services Available to Patients
- Ketamine Exhibits Effective Pain Relief for Refractory Headaches
- Pain In Elite Athletes: IOC Recommendations on Contributing Factors and Treatment Approach
- Naproxen Plus Muscle Relaxants vs Naproxen Monotherapy for Low Back Pain
- Pain Processing: Examining the Role of Oxytocin
- Short- vs Long-Acting Opioids for Osteoarthritis Pain
- Extended-Release Naltrexone Injections Reduce Opioid Dependence
- Depressive Symptoms in Medical Interns Increased With Work-Family Conflicts